Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Girgis RR, et al. Among authors: kapas m. Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15. Psychopharmacology (Berl). 2016. PMID: 27525990 Free PMC article.
Population Pharmacokinetics of Cariprazine and its Major Metabolites.
Periclou A, Phillips L, Ghahramani P, Kapás M, Carrothers T, Khariton T. Periclou A, et al. Among authors: kapas m. Eur J Drug Metab Pharmacokinet. 2021 Jan;46(1):53-69. doi: 10.1007/s13318-020-00650-4. Eur J Drug Metab Pharmacokinet. 2021. PMID: 33141308 Free PMC article.
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z. Gyertyán I, et al. Among authors: kapas m. Neurochem Int. 2011 Nov;59(6):925-35. doi: 10.1016/j.neuint.2011.07.002. Epub 2011 Jul 13. Neurochem Int. 2011. PMID: 21767587
Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.
Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt E, Kiss B, Vastag M, Tihanyi K, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Kapás M, Szombathelyi Z. Agai-Csongor E, et al. Among authors: kapas m. Bioorg Med Chem Lett. 2012 May 15;22(10):3437-40. doi: 10.1016/j.bmcl.2012.03.104. Epub 2012 Apr 4. Bioorg Med Chem Lett. 2012. PMID: 22537450
Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z. Gyertyán I, et al. Among authors: kapas m. J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78. doi: 10.1124/jpet.106.107920. Epub 2006 Dec 14. J Pharmacol Exp Ther. 2007. PMID: 17170312
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Agai Csongor E, Domány G, Kiss B, Szombathelyi Z. Gyertyán I, et al. Among authors: kapas m. Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):529-39. doi: 10.1007/s00210-008-0311-x. Epub 2008 Jun 12. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18548231
28 results